Endocrine-Related Cancer

Expression of FAM129A, KRT7, SOD2 and MME in tissue and serum from metastatic patients. (A) Box and whisker plots were generated from previously published data on metastatic and control cohorts (Taylor et al. 2010). P-values were calculated using Wilcoxon rank-sum test. (B) Immunohistochemistry (IHC) for the four genes on biopsy tissue taken from the patients assayed in Fig. 1. All IHC was performed on the Bondmax Autostainer using the antibodies FAM129A (1:750), KRT7 (2.8 g/L), SOD2 (1:1500) and MME (1:50). Staining is shown in brown colour with nuclei shown in blue colour and was classified into the following categories: none, weak, moderate and high, based on intensity. (C) An ELISA developed on the Meso Scale Discovery platform was used to determine the amount of MME protein in the serum from patients previously tested in the discovery cohort. Plates were coated with goat anti-MME (1.44 μg/mL) and MME protein detected with biotinylated goat anti-MME (1:100) before visualising using streptavidin sulphoTAG (1:1000) and measured using a Sector 6000 plate reader. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0287.